This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DiaDexus, Inc. Reports Fourth Quarter And Full Year 2012 Financial Results

SOUTH SAN FRANCISCO, Calif., March 7, 2013 (GLOBE NEWSWIRE) -- diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2012.

Brian Ward, Ph.D., diaDexus' President and Chief Executive Officer, said, "In 2012 we successfully executed the initial phase of our growth strategy by driving adoption of the PLAC Test, expanded reimbursement, launched the Activity Test in Europe and began development on a new product pipeline. We also achieved 27% revenue growth for the year and our tenth consecutive quarter of year-over-year revenue growth. Improvement in gross margin and prudent expense management moved us closer to achieving profitability."

Total revenues for the fourth quarter 2012 were $5.4 million, an 11% increase over $4.9 million reported in the fourth quarter of 2011. Demand for the PLAC Test remained strong with volume increases outpacing pricing pressure. As a result, gross margins in the fourth quarter of 2012 improved to 74% compared to 67% for the same quarter in 2011. Total operating expenses for the quarter were $5.7 million, compared to $5.8 million for the fourth quarter of 2011. The decrease in operating expenses resulted from lower general and administrative expenses, along with reduced product, and research and development costs. These savings were partially offset by higher sales and marketing expenses in the fourth quarter of 2012 compared to the fourth quarter of 2011. The Company's net loss for the fourth quarter 2012 narrowed to $0.4 million, or $(0.01) per share, from a net loss of $1.0 million, or $(0.02) per share, in the fourth quarter of 2011.

Total revenues for the full year 2012 were $20.8 million, a 27% increase over $16.4 million reported for the full year 2011, reflecting increased demand for the PLAC test. Gross margins for the full year 2012 improved to 70% compared to 67% for the prior year. Total operating expenses for the full year 2012 were $23.2 million, compared to $24.2 million for the full year 2011. The decrease in operating expenses resulted from lower general and administrative and research and development costs, partially offset by higher sales and marketing expenses in full year 2012 compared to the full year 2011. The Company's net loss for the full year 2012 narrowed to $2.8 million, or $(0.05) per share, from a net loss of $7.5 million, or $(0.14) per share, in the full year 2011.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs